These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8293759)

  • 21. Class III antiarrhythmic action linked with positive inotropy: antiarrhythmic, electrophysiological, and hemodynamic effects of the sea-anemone polypeptide ATX II in the dog heart in situ.
    Platou ES; Refsum H; Hotvedt R
    J Cardiovasc Pharmacol; 1986; 8(3):459-65. PubMed ID: 2425158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of the clinical pharmacology of antiarrhythmic drugs.
    Woosley RL; Funck-Brentano C
    Am J Cardiol; 1988 Jan; 61(2):61A-69A. PubMed ID: 2447771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.
    Campbell TJ
    Cardiovasc Drugs Ther; 1992 Oct; 6(5):519-28. PubMed ID: 1333276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flecainide-induced prolongation of ventricular repolarization contributes to the proarrhythmic profile of action.
    Osadchii OE
    Int J Cardiol; 2015 Oct; 197():81-2. PubMed ID: 26142191
    [No Abstract]   [Full Text] [Related]  

  • 26. Modernized Classification of Cardiac Antiarrhythmic Drugs.
    Lei M; Wu L; Terrar DA; Huang CL
    Circulation; 2018 Oct; 138(17):1879-1896. PubMed ID: 30354657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reverse use dependence of antiarrhythmic class Ia, Ib, and Ic: effects of drugs on the action potential duration?
    Langenfeld H; Köhler C; Weirich J; Kirstein M; Kochsiek K
    Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2097-102. PubMed ID: 1279606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple cellular electrophysiological effects of a novel antiarrhythmic furoquinoline derivative HA-7 [N-benzyl-7-methoxy-2,3,4,9-tetrahydrofuro[2,3-b]quinoline-3,4-dione] in guinea pig cardiac preparations.
    Chang GJ; Su MJ; Kuo SC; Lin TP; Lee YS
    J Pharmacol Exp Ther; 2006 Jan; 316(1):380-91. PubMed ID: 16174797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel antiarrhythmic compounds with combined class IB and class III mode of action.
    Mátyus P; Varga I; Rettegi T; Simay A; Kállay N; Károlyházy L; Kocsis A; Varró A; Pénzes I; Papp JG
    Curr Med Chem; 2004 Jan; 11(1):61-9. PubMed ID: 14754426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What should we expect from the next generation of antiarrhythmic drugs?
    Camm AJ; Yap YG
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):307-17. PubMed ID: 10090237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Utilization of anti-arrhythmic drugs].
    Perrenoud JJ
    Schweiz Med Wochenschr; 1980 Jul; 110(29):1090-6. PubMed ID: 6999615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New evolvement of antiarrhythmic drugs].
    Kanno M
    Nihon Yakurigaku Zasshi; 1993 Sep; 102(3):215-23. PubMed ID: 8406233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Principles for the classification of anti-arrhythmia agents in cardiac arrhythmias].
    Ravens U
    Z Kardiol; 1992; 81 Suppl 4():119-25. PubMed ID: 1290288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
    Antoni H; Weirich J
    Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiarrhythmic drug therapy: new drugs and changing concepts.
    Reiser HJ; Sullivan ME
    Fed Proc; 1986 Jul; 45(8):2206-12. PubMed ID: 2873062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on antiarrhythmic drug pharmacology.
    Huang CL; Wu L; Jeevaratnam K; Lei M
    J Cardiovasc Electrophysiol; 2020 Feb; 31(2):579-592. PubMed ID: 31930579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proarrhythmic effects of antiarrhythmic drugs.
    Ross DL; Cooper MJ; Koo CC; Skinner MP; Davis LM; Richards DA; Uther JB
    Med J Aust; 1990 Jul; 153(1):37-47. PubMed ID: 2199804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
    Milberg P; Frommeyer G; Uphaus T; Kaiser D; Osada N; Breithardt G; Eckardt L
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):92-100. PubMed ID: 21964157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.